1[1]Singh M, O'Hagan D.Advances in vaccine adjuvants [J]. Nat Biotechnol,1999,17(11):1075-1081.
2[2]Cox JC, Coulter AR. Adjuvants-a classification and review of their modes of action[J].Vaccine,1997,15(3):248-256.
3[3]Audibert MF, Lise LD. Adjuvants: current status, clinical perspectives and future prospects[J].Immunol Today,1993,14(6):281-284.
4[4]Wagland BM, McClure SJ, Cossey SG, et al. Effect of Freund's adjuvants on guinea pigs infected with, or vaccinated against, Trichostrongylus colubriformis[J].Int J Parasitol,1996,26(1):85-90.
5[5]Briand EJ, Ruble GR, Stiteler J, et al. Comparison of adjuvants with Leishmania antigens in a guinea pig model to induce delayed-type hypersensitivity responses[J].Lab Anim Sci,1999,49(5):519-521.
6[6]Aucouturier J, Deville S, Perret C,et al. Assessment of efficacy and safety of various adjuvant formulations with a total soluble extract of Trichinella spiralis[J].Parasite,2001,8(2 Suppl):S126-132.
7[7]Lawrence G, Saul A,Giddy AJ,et al. Phase I trial in humans of an oil-based adjuvant seppic montanide ISA 720[J].Vaccine,1997,15(2):176-178.
8[8]Saul A, Lawrence G, Smillie A, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant[J].Vaccine,1999,17(23-24):3145-3159.
9[9]Gupta RK. Aluminum compounds as vaccine adjuvants[J]. Adv Drug Deliv Rev,1998,32(3):155-172.
10[10]Matsumoto S, Yukitake H, Kanbara H, et al. Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1[J].Vaccine,1999,18(9-10):832-834.
同被引文献11
1Genton B, Betuela I, Felger I, et al. A recombinant blood- stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea [J]. J Infect Dis, 2002,185 (6) : 820-827.
2Audran R, Cachat M, Spertini F, et al. Phase I malaria vaccine trail with a long synthetic peptide derived from the merozoite surface protein 3 antigen [J]. Infect Immun, 2005, 73(12) : 8017-8026.
3Sirima Sodiomon B, Nebie I, Ouedraogo A, et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa [J]. Vaccine, 2007,25(14):2723-2732.
4Polley Spencer D, Tetteh Kevin KA, Lloyd Jennie M, et al. Plasmodium folciparum merozoite surface protein 3 is a target of Allele-specific immunity and Alleles are maintained by natural selection [J]. J Infect Dis, 2007,195(2):279-287.
5Bouharoun-Tayoun H, Noun G, Druilhe P, et al. Plasmodium falciparum: production of human antibodies specific for the MSP-3 protein in the Hu-SPL-SCID mouse [J]. Exp Parasitol, 2004, 108(1-2) :47-52.
6Oeuvray C, Bouharoun-Tayoun Merozoite surface rotein-3: H, Gras-Masse H, et al. A malaria protein inducing antibodies that promote Hasmodium falciparum killing by cooperation with blood monocytes [J]. Blood, 1994,84(5): 1594-1602.
7Singh S, Soe S, Mejia JP, et al. Identification of a conserved region of MSP3 targeted by biologically active antibodies to improve vaccine design [J]. J Infect Dis, 2004,190(5): 1010-1018.
8Davis HL, Weeratna R, Waldschmidt TJ, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen [J]. J Immunol, 1998,160(2) :870-876.
9Holder AA, Guevara Patino JA, Uthaipibull C, et al. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria [J]. Parassitol, 1999,41 (1-3) :409-414.
10Weiqing Pan, Daqing Huang, Qingfeng Zhang, et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro [J]. J Immunol, 2004,172(10): 6167-6174.
